uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS
LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...
biopharma-reporter3h
FDA approves Pfizer's antibody treatment for hemophilia
The approval of Hympavzi makes it the first treatment for both hemophilia A and B to be administered through a pre-filled pen ...
BioPharma Dive18h
Pfizer drug for hemophilia approved by FDA
The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.
hemophilianewstoday21h
What does a minor cut do to someone with hemophilia?
Columnist Alliah Czarielle clears up some common misconceptions about what happens when people with hemophilia have minor cuts or abrasions.
Zacks.com on MSN22h
Pfizer Secures FDA Approval for Hemophilia Drug Hympavzi
Pfizer PFE announced that the FDA has approved its subcutaneously administered drug marstacimab for treating certain ...
FDA Approves Pfizer's Second Hemophilia Drug With Six Months
Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...